Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a 30-Minute infusion be as safe as an hour for kids with IBD?

NCT ID NCT06839820

Symptom relief Sponsor: University Hospital, Akershus Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares giving the drug infliximab over 30 minutes versus the standard 60 minutes in children with inflammatory bowel disease (IBD). The goal is to see if the shorter infusion causes just as few allergic reactions and improves patient and nurse satisfaction. Sixty children aged 1-17 who have already had at least 5 infliximab infusions will each receive 8 infusions, alternating between the two speeds.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
infliximab
What this could lead to
If successful, this could allow children with IBD to receive infliximab infusions in half the usual time, reducing clinic visits and improving quality of life.
What could go wrong
This is a small, early-stage study with only 60 participants. Faster infusions may still cause more allergic reactions, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

1 year to 18 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Pediatric IBD patients on infliximab * 1-17 years * Received at least 5 infusions of infliximab prior to entry in the study Exclusion Criteria: * Receiving infliximab for non-IBD condition (reumatological or other causes) * previous severe infliximab infusion reaction * need for an interpreter * heart failure with hemodynamic impact * unwillingness to participate

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IBD (inflammatory bowel disease) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

inflammatory bowel disease irritable bowel syndrome Patient Satisfaction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IBD (inflammatory bowel disease) Infliximab Infusion Patient satisfaction

Contacts and locations

Locations

  • Akershus University Hospital

    Lørenskog, 1478, Norway

More trials for these conditions

Other studies related to the condition(s) this trial covers.